Should You Buy Teva Pharmaceutical Industries Limited Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Teva Pharmaceutical Industries Limited (TEVA) occupies a solid middle-ground position with a Quality of Company score of 6.7/10. At the current market price of $39.25, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 3 of 11 CirclFi valuation models project upside for Teva Pharmaceutical Industries Limited (TEVA) at $39.25 — the model consensus leans bearish, with a Quality Score of 6.7/10 and Value-Trap risk of 33/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Teva Pharmaceutical Industries Limited (TEVA) in 2026?
What Is the Bull Case vs the Bear Case for Teva Pharmaceutical Industries Limited (TEVA)?
| Bull case — $61.68 target (+57.1%) | Bear case — $4.40 target (-88.8%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $61.68 (+57.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $4.40 (-88.8%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry tailwind: orphan drug designation could provide meaningful support for Teva Pharmaceutical Industries Limited's revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +145.9% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry headwind: patent expiration revenue loss represents a meaningful risk for Teva Pharmaceutical Industries Limited and its Drug Manufacturers - Specialty & Generic peers. |
How Does TEVA Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: ANIK · AKBA · MRMD · ADCT · BHC · ACB · TKNO · CTOR · COLL · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like TEVA on Quality?
Closest companies to TEVA’s Quality of Company score of 6.7/10, across all industries.
- VSAT — Viasat, Inc. (QOC 6.7) · analysis
- AXTI — AXT, Inc. (QOC 6.7) · analysis
- BCYC — Bicycle Therapeutics plc (QOC 6.7) · analysis
- CCEL — Cryo-Cell International, Inc. (QOC 6.7) · analysis
- NAT — Nordic American Tankers Limited (QOC 6.7) · analysis
- LASR — nLIGHT, Inc. (QOC 6.7) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does TEVA Appear In?
So Is Teva Pharmaceutical Industries Limited (TEVA) Worth Buying in 2026?
Caution dominates our read on Teva Pharmaceutical Industries Limited at $39.25. 8 of 11 models see limited upside or outright downside, with the median fair value at $20.78 (-47.1%). Quality at 6.7/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Teva Pharmaceutical Industries Limited's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About TEVA Stock?
Should I buy TEVA stock right now?
Based on CirclFi's multi-model analysis, 3 of 11 models see upside for TEVA at $39.25. The models are divided, which means the investment case depends heavily on your assumptions about Teva Pharmaceutical Industries Limited's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Teva Pharmaceutical Industries Limited?
Key risks include: wide model disagreement (1301% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does TEVA compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, TEVA holds a Quality Score of 6.7/10. Comparable companies include ANIK (QOC 6.8), AKBA (QOC 6.6), MRMD (QOC 6.8). The relative ranking helps investors identify whether TEVA offers better fundamental quality than alternatives in the same sector.
Is TEVA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. TEVA's Quality Score of 6.7/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy TEVA at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $4.40 to $61.68. At $39.25, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for TEVA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad